Navigation Links
NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures
Date:8/19/2010

ROCKVILLE, Md., Aug. 19 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) President and CEO Dr. Rahul Singhvi today attended the press briefing by U.S. Health and Human Services Secretary Kathleen Sebelius and other public health officials announcing a $2 billion plan to accelerate the development of drugs and vaccines to prevent the spread of infectious diseases and issued the following statement of support for the plan's five key initiatives:

  • Define and strengthen FDA regulatory processes to support countermeasures
  • Create a flexible manufacturing and core services organization as a center of excellence
  • Create a new program to nurture early-stage discovery concepts
  • Upgrade influenza vaccine manufacturing with new technology
  • Create strategic investment fund to develop counterterrorism technology

Dr. Singhvi stated: "I was pleased to attend today's briefing by Secretary Sebelius and fully support the reforms proposed to improve our nation's ability to respond to disease outbreaks such as pandemic influenza.  My colleagues at Novavax and I share the government's sense of urgency about accelerating the development and delivery of new vaccines to prevent the spread of infectious diseases as a result of a natural outbreak or a biological attack and have committed our company to the achievement of this goal.  

"We believe our unique recombinant technology can help play a key role in solving the problems of vaccine supply, timely preparation and availability and that our vaccines have the potential to prevent the spread of seasonal and pandemic influenza, including H1N1, and other infectious diseases described in today's report.   The proposal to create more rapid and flexible U.S. manufacturing capabilities and use new production technologies to transform our nation's response capability is perfectly aligned with our company's technology focus and commercial strategy and we support its adoption."

Dr. Singhvi was also cited as a contributor to the new plan, entitled "Report to the President on Reengineering the Influenza Vaccine Production Enterprise to Meet the Challenges of Pandemic Influenza," which was prepared by the President's Council of Advisors on Science and Technology and summarized at today's briefing by Secretary Sebelius, FDA Commissioner Dr. Peggy Hamburg, CDC Director Dr. Tom Friedman, BARDA Director Dr. Robin Robinson, NIAID Director Dr. Anthony Fauci, and Assistant Secretary for Preparedness and Response Dr. Nicole Lurie.  The full report is available online at http://www.whitehouse.gov/sites/default/files/microsites/ostp/PCAST-Influenza-Vaccinology-Report.pdf.  Secretary Sebelius's remarks are available online at http://www.hhs.gov/secretary/about/speeches/sp20100819.html.

About Novavax

Novavax, Inc. is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like-particle (VLP) technology. The company produces potent VLP-based recombinant vaccines utilizing new and efficient manufacturing approaches. Novavax is committed to using its VLP technology to create country-specific vaccine solutions. The company has formed a joint venture with Cadila Pharmaceuticals, named CPL Biologicals, to develop and manufacture vaccines, biological therapeutics and diagnostics in India. Additional information about Novavax is available on the company's website: www.novavax.com.

Cautionary Note Regarding Forward-Looking Statements

Statements herein relating to future performance, conditions or strategies are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. We caution readers not to place significant reliance on forward-looking statements contained in this release. Factors that may cause actual results to differ materially from the results discussed in forward-looking statements are contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov, including the factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, as updated by our Quarterly Reports on Form 10-Q for the quarter ended March 31, 2010 and June 30, 2010. These forward-looking statements speak only as of the date of this earnings release and Novavax assumes no duty to update such statements.


'/>"/>
SOURCE Novavax, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novavax CEO to Present at ACUMENBioFins 9th Annual Healthcare Conference
2. Novavax Reports Third Quarter 2007 Financial Results and Progress with Vaccine Development Programs
3. GE Healthcare and Novavax Establish Collaboration To Develop and Market Pandemic Influenza Solution
4. Novavax Announces Preclinical Results for Seasonal Influenza Vaccine Program
5. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
6. Novavax Reports Fourth Quarter and 2007 Year-End Financial Results
7. Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate
8. Novavax Completes Enrollment in Phase I/IIa Pandemic Influenza Vaccine Clinical Trial
9. Novavax Announces Proprietary Method to Create SARS Vaccine and Renewal of NIH Funding for SARS Vaccine Development
10. Novavax to Present Phase I/IIa Trial Data Results in an Investor Conference Call on August 26, 2008
11. Novavax Announces Favorable Results from Phase I/IIa Pandemic Influenza Vaccine Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of ... Forecast to 2022" report to their offering. ... The global wound care market was worth $24,482.9 ... of 6.7% during 2016-2022 Among the various wound care products ... the global market in 2015. Among the various applications, surgical wound segment ...
(Date:3/24/2017)... 2017   The Accreditation Council for Medical ... in the pharmaceutical industry has appointed Dr. ... newly formed scientific advisory board. Dr. Chin will ... first ever medical affairs think tank within the ... the ACMA, please visit  www.medicalaffairsspecialist.org .  Connect ...
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the ... Inc., projects that the global medical cannabis market will reach a value ... is a major market for the new growing industry. By the end ... legally buy and sell medical cannabis. More conservative states like ...
Breaking Medicine Technology:
(Date:3/27/2017)... and Lake Orion, Michigan (PRWEB) , ... March ... ... weight loss results. The comprehensive weight management program at Women’s Excellence will ... with an initial evaluation and physical exam. The specialists at Women's Excellence ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Association of Healthcare and ... hold their first Northeast Regional AHVAP Meeting. For 2017, Dr. Hayes will provide ... and value analysis professionals have a ‘seat at the table’ with clinical committees ...
(Date:3/27/2017)... ... , ... According to the American Cancer Society , the average 15-year ... Once the cancer spreads to other organs, bones, or lymph nodes, however, the 5-year ... this latter group, tune in to Lifestyle Magazine on April 9, 2017, ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... industry. Conventional sodium testing methods are complicated and require expert user knowledge. In ... new analytical method dedicated to the simplified, yet highly accurate, determination of sodium. ...
Breaking Medicine News(10 mins):